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AbstrACt
Objectives To provide an accurate, web-based tool 
for stratifying patients with atrial fibrillation to facilitate 
decisions on the potential benefits/risks of anticoagulation, 
based on mortality, stroke and bleeding risks.
Design The new tool was developed, using stepwise 
regression, for all and then applied to lower risk patients. 
C-statistics were compared with CHA2DS2-VASc using 
30-fold cross-validation to control for overfitting. External 
validation was undertaken in an independent dataset, 
Outcome Registry for Better Informed Treatment of Atrial 
Fibrillation (ORBIT-AF).
Participants Data from 39 898 patients enrolled in the 
prospective GARFIELD-AF registry provided the basis for 
deriving and validating an integrated risk tool to predict 
stroke risk, mortality and bleeding risk.
results The discriminatory value of the GARFIELD-AF 
risk model was superior to CHA2DS2-VASc for patients 
with or without anticoagulation. C-statistics (95% CI) for 
all-cause mortality, ischaemic stroke/systemic embolism 
and haemorrhagic stroke/major bleeding (treated 
patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) 
and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-
AF risk models, and 0.66 (0.64–0.67), 0.64 (0.61–0.66) 
and 0.64 (0.61–0.68), respectively, for CHA2DS2-VASc (or 
HAS-BLED for bleeding). In very low to low risk patients 
(CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the 
CHA2DS2-VASc and HAS-BLED (for bleeding) scores 
offered weak discriminatory value for mortality, stroke/
systemic embolism and major bleeding. C-statistics 
for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 
0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end 
point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 
to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or 
HAS-BLED for bleeding). Upon validation in the ORBIT-AF 
population, C-statistics showed that the GARFIELD-AF 
risk tool was effective for predicting 1-year all-cause 
mortality using the full and simplified model for all-cause 
mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 
to 0.77), respectively, and for predicting for any stroke or 
systemic embolism over 1 year, C-statistics 0.68 (0.62 to 
0.74).
Conclusions Performance of the GARFIELD-AF risk tool 
was superior to CHA
2DS2-VASc in predicting stroke and 
mortality and superior to HAS-BLED for bleeding, overall 
and in lower risk patients. The GARFIELD-AF tool has the 
potential for incorporation in routine electronic systems, 
and for the first time, permits simultaneous evaluation of 
ischaemic stroke, mortality and bleeding risks.
Clinical trial registration URL: http://www. clinicaltrials. 
gov. Unique identifier for GARFIELD-AF (NCT01090362) 
and for ORBIT-AF (NCT01165710).
IntrODuCtIOn
Guidelines recommend the use of oral antico-
agulants (OACs), either oral vitamin K antag-
onists (VKAs, eg, warfarin) or non-VKA oral 
anticoagulants (NOACs), for stroke preven-
tion in patients with atrial fibrillation (AF) 
and a risk of stroke.1–3 Anticoagulation is 
recommended by guidelines in patients with 
at least one risk factor for stroke, as defined 
by CHA2DS2-VASc (Congestive heart failure 
(CHF)/left ventricular dysfunction, Hyper-
tension, Age≥75 (doubled), Diabetes, Stroke 
(doubled) – Vascular disease, Age 65–74 and 
Sex category (female)).1 4 Although the rela-
tionship between increasing CHA2DS2-VASc 
risk score values and stroke risk is well defined, 
there remains clinically important uncertainty 
in defining the population at truly low risk of 
stroke. Among such patients, the benefits of 
OACs may not exceed the risks of bleeding.3 
In the derivation of the CHADS2 and CHA2DS2-
VASc risk scores, relatively few very low to low 
risk patients were included in these analyses 
(eg, in the derivation of CHA2DS2-VASc, 103 
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patients had a score of 0, and 162 patients a score of 1 out 
of 1084 patients evaluated by Lip and colleagues, 2010).4 5 
Large-scale international registry programmes demon-
strate substantial divergence in clinical practice compared 
with guideline recommendations.6 For example, the 
Global Anticoagulant Registry in the FIELD-Atrial Fibril-
lation (GARFIELD-AF) registry observed that between 
46% (2010–2011) and 59% (2014–2015) of patients with 
a CHA2DS2-VASc score of 0 or 1 were anticoagulated.
7 
In part, this clinical uncertainty reflects the poor predic-
tive value of CHA2DS2-VASc, especially in very low to low 
stroke risk patients (CHA2DS2-VASc score of 0 or 1 (men) 
and 1 or 2 (women)). It may also reflect other factors 
such as the introduction of NOACs, for example, with the 
increasing use of this new class of treatment for patients 
at all levels of stroke risk, including those patients with a 
very low stroke risk (CHA2DS2-VASc score of 0).
7 Thus, 
clinicians are basing their decision to anticoagulate on 
factors beyond those employed in conventional scores of 
stroke risk. Unless the risks of ischaemic stroke and major 
bleeding are accurately characterised for such patients 
using contemporary databases, it is not possible to weigh 
the potential benefits of anticoagulation against the 
hazards of bleeding. For this reason, we have developed 
an integrated risk tool that allows simultaneous calcula-
tion of not only ischaemic stroke risk but also and major 
bleeding risk and all-cause mortality to help facilitate 
greater guideline adherence.
In this report, we compare the predictive value of this 
new integrated risk assessment tool with the CHA2DS2-
VASc risk tool for the overall population, and then in very 
low to low risk patients (CHA2DS2-VASc score of 0 or 1 
(men) and 1 or 2 (women)), that is, in those patients in 
whom OAC is not recommended by the ESC. The 2016 
European Society of Cardiology (ESC) Guidelines recom-
mend OAC therapy only in patients with at least two risk 
factors for stroke, that is, CHA2DS2-VASc risk score of 2 or 
more in men and 3 or more in women.6 As a sensitivity 
analysis, we also evaluated those with a CHA2DS2-VASc 
score of 0, 1 and 2 (men) and 1, 2 and 3 (women).
MAterIAls AnD MethODs
Design
The new risk stratification tool was derived from prospec-
tive data gathered between March 2010 and July 2015 
from the GARFIELD-AF registry, undertaken in 35 coun-
tries in adults with recently diagnosed AF.8 Models were 
trained on indicators for three events (all-cause mortality, 
ischaemic stroke/systemic embolism (SE) and any major 
bleed) that occurred within 1 year of enrolment. The 
derivation of the GARFIELD-AF risk models used similar 
statistical methods as for the GRACE model for risk strat-
ifying patients with acute coronary syndrome (ACS),9 
with C-statistics estimated from regression models.10 
Analogous to other bleeding models, only patients from 
GARFIELD-AF on OACs were used in developing the 
model for major bleeding.
Comparisons of the performance of the new 
GARFIELD-AF risk models were made with (A) CHA2DS2-
VASc score (for all-cause mortality and ischaemic stroke/
SE) and (B) HAS-BLED score for major bleeding. The 
performance of the new risk schemas was tested in the 
whole GARFIELD-AF population as well as in patients 
treated and untreated with OACs for stroke prevention 
at baseline, and so permitting a better comparison with 
CHA2DS2-VASc.
We also tested our hypothesis that the performance of 
the GARFIELD-AF risk model would be better than the 
CHA2DS2-VASc score in discriminating between patients 
with a lower stroke risk. To be consistent with the 2016 
ESC Guidelines, we considered a CHA2DS2-VASc score of 
0 or 1 (men) and 1 or 2 (women) as representative of 
very low to low stroke risk.6 As a sensitivity analysis, we also 
evaluated those with a CHA2DS2-VASc score of 0–2 (men) 
and 1–3 (women).
Subsequently, a simplified risk tool for all-cause mortality 
was derived to facilitate wider potential application of 
the GARFIELD-AF risk model in electronic systems. The 
model for ischaemic stroke/SE contained sufficiently few 
factors to be potentially used as a web-based tool without 
simplification, that is, world region, age, race, history of 
stroke, history of bleeding, heart failure, renal disease 
and use of OAC. Similarly, the full model for major 
bleeding, based on a subset of 25 677 patients who were 
on OACs, was also developed as a web tool using: age, 
vascular disease and kidney disease.
The validity of the GARFIELD-AF risk models for all 
end points and the simplified GARFIELD-AF model for 
all-cause mortality was tested externally in patients with 
AF from an entirely independent US-based registry—the 
Outcome Registry for Better Informed Treatment of Atrial 
Fibrillation (ORBIT-AF) registry.11–14 As part of the valida-
tion, the GARFIELD-AF model was also compared with 
the Anticoagulation and Risk factors in Atrial Fibrillation 
(ATRIA) score in predicting major bleed in patients on 
OAC treatment.
registry population
The analysis was conducted in 39 898 patients enrolled 
in GARFILED-AF between March 2010 and July 2015 
(cohort 1: March 2010–October 2011; cohort 2: August 
2011–June 2013; cohort 3: April 2013–October 2014 
and cohort 4: March 2014–July 2015). The data were 
extracted from the study database on 28 July 2016. To 
minimise recruitment bias in GARFIELD-AF, investi-
gator sites were selected randomly from representative 
care settings in each participating country (apart from 
18 sites, out of >1000) and consecutive patients were 
enrolled, regardless of whether or not they received 
antithrombotic treatment. Eligible patients comprised 
adults (aged ≥18 years) who had been diagnosed with 
AF (not related to mechanical valves or severe valve 
disease, ie, non-valvular) within the previous 6 weeks and 
had at least one risk factor for stroke as judged by the 
investigator (a complete list of investigators is given in 
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the online supplementary file). These risk factors were 
not prespecified in the protocol, nor were they limited 
to the components of risk stratification schemes, such as 
CHA2DS2-VASc. Patients with a transient reversible cause 
of AF and those for whom follow-up was not envisaged or 
possible were excluded.
study procedures and outcome measures
The methods employed in GARFIELD-AF have been 
published.15 16 In brief, baseline characteristics included: 
patient characteristics, medical history, care settings, type 
of AF, date and method of diagnosis, symptoms of AF, 
type of anticoagulant treatment (VKAs, factor Xa inhibi-
tors and direct thrombin inhibitors, as well as antiplatelet 
treatment (AP)).8
Data on components of the CHA2DS2-VASc
17 and 
HAS-BLED18 risk stratification schemes were also collected 
to assess the risks of ischaemic stroke and major bleeding. 
Collection of follow-up data occurred at 4-monthly inter-
vals based on telephone interviews and hospital records 
up to 24 months. The incidence of ischaemic stroke, tran-
sient ischaemic attack (TIA), SE, ACS, hospitalisation, 
death (cardiovascular and non-cardiovascular), CHF 
(occurrence or worsening) and bleeding (severity and 
location) was documented. An audit and quality control 
programme was applied,19 and data were examined for 
completeness and accuracy by the coordinating centre 
(TRI, London, UK). By design, 20% of all electronic case 
report forms in the GARFIELD-AF registry were moni-
tored against source documentation at sites over the 8 
years of recruitment and follow-up.19
Definitions of end points and analytical methods
Major bleed was classified by investigators according to 
the International Society on Thrombosis and Haemostasis 
definition. Stroke/SE were defined as the combined end 
points of: ischaemic stroke, SE and TIA. Major bleeds, 
including intracranial bleeds, were defined as a combined 
end point of: haemorrhagic stroke and any major bleed.
Vascular disease included patients with peripheral 
artery disease and/or coronary artery disease (CAD) with 
or without a history of ACS. Hypertension was defined as 
a documented history of hypertension or blood pressure 
>140/90 mm Hg. Chronic kidney disease (CKD) was clas-
sified by investigators according to the National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative 
guidelines into two groups20: moderate-to-severe, or mild 
or none. CHF was defined as a history (cohorts 1 and 2) 
or current or prior history of CHF (cohorts 3 and 4).
The CHA2DS2-VASc score was the sum of points after 
addition of one point each for CHF, hypertension, 
diabetes, vascular disease, age 65–74 years and female 
gender, and two points each for age ≥75 years and previous 
SE. This score ranged from 0 to 9.17 The HAS-BLED score 
was the sum of points after addition of one point each 
for hypertension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, labile international 
normalised ratios, elderly (>65 years) and drugs/alcohol 
concomitantly18 (fluctuations in international normalised 
ratios were not included).
statistical modelling
Four methods of model generation were applied: coales-
cent regression, ridge regression, stepwise regression and 
random forest. Thirty-fold cross-validation was applied in 
each instance during the modelling process. Since step-
wise regression is familiar to most clinicians, the approach 
was used for the primary analysis. The results from this 
process were applied using a P value of 0.01 to enter and 
0.05 to stay in the model. Variables considered in the full 
model were: race, world region, type of AF at diagnosis, 
baseline use of NOAC or VKA, the composite of ADP 
or P2Y12 receptor inhibitors, aspirin, the composite of 
non-steroidal anti-inflammatory drugs (NSAIDs) or cyclo-
oxygenase-2 (Cox-2) inhibitors, and/or AP treatments for 
AF, gender, systolic and diastolic blood pressures, heart 
rate, age, current CAD or a history of stable angina, stent 
placement, myocardial infarction (MI), unstable angina, 
coronary artery bypass surgery (CABG), aortic disease, 
peripheral vascular disease, carotid disease, CKD, hyper-
tension, stroke, TIA, SE, cirrhosis, current hypertension, 
a history of CHF or an ejection fraction less than 40, sleep 
apnoea and heavy alcohol consumption. Follow-up was 
censored at 1 year for those patients who were followed 
for a longer period. Comparison of the GARFIELD-AF 
risk model with existing scores (CHA2DS2-VASc and 
HAS-BLED) was performed using two measures: display 
of C-index with 95% CI for a measure of discrimination 
and P values for the added value of each model to a 
‘super’ model. In the latter case, one assumes the super 
model to include two factors: patient values multiplied by 
their respective model coefficients for the GARFIELD-AF 
risk model plus the score of interest. The difference in 
likelihood ratio test evaluates the added information of 
one model given the information from the other. If statis-
tically significant, the model contains additional predic-
tive information. If not significant, the first model alone 
contains most of the information in both. A third measure 
of the quality of the model is the calibration curves, which 
show how well the predicted values are calibrated to the 
actual rates observed. The eight factors with the largest 
Wald Chi-Squares (χ2) were retained for the simplified 
model for all-cause mortality. Model coefficients were 
then regenerated on this reduced set of factors. For the 
other two models, few enough factors were retained with 
the stepwise process so that no further reduction in the 
number of variables was needed.
external validation
We evaluated the performance of the GARFIELD-AF 
risk model in an external AF population using data from 
ORBIT-AF, a prospective registry of 10 132 patients with 
incident or prevalent AF (2010–2012).11 Each score was 
recreated according to the definitions given in the orig-
inal GARFIELD-AF study, using baseline values from the 
first study visit in each registry. From the list of variables 
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in the simplified model, only history of bleeding was 
unavailable in ORBIT-AF. History of gastrointestinal (GI) 
bleeding was substituted. The full list of definitions used 
to generate the scores in each dataset is provided in online 
supplementary table 1. Online supplementary table 2 
details the Wald χ2, P values and hazard ratio (HRs) for 
each component of the simplified GARFIELD-AF models 
for: all-cause mortality, ischaemic stroke/SE and major 
bleeding, including haemorrhagic stroke.
results
Table 1 provides the baseline characteristics for patients 
(n=38 935 with CHA2DS2-VASc scores) and for patients 
stratified as either very low to low risk (CHA2DS2-VASc 0 
or 1 for men and 1 or 2 for women; 20.2% of patients). 
Higher risk was classified as CHA2DS2-VASc score ≥2 for 
men and ≥3 for women.
The 1 year Kaplan-Meier event rates by CHA2DS2-VASc 
score are given in figure 1. Event rates were rare in the 
very low to low risk cohort: 1.3% all-cause mortality, 
0.5% ischaemic stroke/SE and 0.5% with haemorrhagic 
stroke/major bleed. By comparison, the respective rates 
for each event in the cohort identified for the sensitivity 
analysis (CHA2DS2-VASc of 0–2 for men, 1–3 for women; 
comprising 45.1% of patients in GARFIELD-AF) were: 
4.9%, 1.5% and 1.2% (table 2); baseline characteristics 
for this cohort are in described online in supplementary 
table 3.
Performance of ChA2Ds2-VAsc and GArFIelD-AF risk models
For all-cause mortality, the GARFIELD-AF risk model 
performed well in the overall population (C-index 0.77) 
(both treated and untreated with OAC) as well as in the 
lower risk groups (C-indices ranged from 0.69 to 0.72) 
(table 3 and the receiver operating characteristic (ROC) 
curves in figure 2). The discriminatory power of the 
model to identify patients at risk of ischaemic stroke/
SE had a C-index of 0.69 (in lower risk groups, C-indices 
ranged from 0.65 to 0.67) (table 3). The calibration 
curves (figure 3) showed that the estimates were closely 
aligned to actual rates for death and displayed adequate 
calibration for other two end points, in particular, in the 
lower risk groups.
The GARFIELD-AF risk model for any major bleeding 
(including haemorrhagic stroke) was based on the subset 
of 25 677 patients who were on an OAC therapy for AF. 
This bleeding model had an overall C-index of 0.66 (95% 
CI 0.62 to 0.69) (table 3).
Table 3 compares the performance of the CHA2DS2-
VASc (or HAS-BLED for bleeding) and GARFIELD-AF 
risk models in the overall population and in lower risk 
populations, respectively. The analyses showed that in 
the overall population, the discriminatory value of the 
GARFIELD-AF integrated risk model was superior to 
CHA2DS2-VASc for all-cause mortality, for stroke/SE 
and for major bleeding (overall population, table 3). 
GARFIELD-AF risk models contain information beyond 
that found in CHA2DS2-VASc or HAS-BLED in the overall 
population as well as in treated and untreated patients 
(p<0.001 for comparisons).
The GARFIELD-AF model also discriminated risk in 
the very low to low risk patients (CHA2DS2-VASc 0 or 
1 for men and 1 or 2 for women) and in those in the 
sensitivity analysis with a higher risk of stroke (CHA2DS2-
VASc 0–2 for men and 1–3 for women) (table 3). 
Compared with CHA2DS2-VASc or HAS-BLED, the 
GARFIELD-AF models provided additional information 
for all endpoints except bleeding in the lower risk groups 
(p<0.001, p<0.004 and p<0.299). In contrast, CHA2DS2-
VASc offered poor discrimination (C-statistic in low-risk 
patients was 0.50 for mortality and 0.59 for ischaemic 
stroke/SE, table 3). CHA2DS2-VASc and HAS-BLED did 
not add information over the GARFIELD-AF risk score 
for any endpoint in the lower risk cohorts (P values 
ranged from 0.087 to 1.00).
For patients with no risk factors other than gender, as 
identified by the CHA2DS2-VASc score (‘very low’ stroke 
risk), only 4 out of these 1579 patients experienced a 
stroke or SE and only 3 out of the 685 anticoagulated 
patients experienced a major bleed.
Performance of the simplified GArFIelD-AF mortality risk 
predictor
A simplified GARFIELD-AF risk model (potentially suit-
able for web applications) was developed for all-cause 
mortality. It included the following variables: age, pulse, 
systolic blood pressure, a history of vascular disease, 
history of bleeding, heart failure, renal disease and use of 
OAC. This model had a C-statistic of 0.77 (95% CI 0.76 to 
0.78) in the GARFIELD-AF population of 39 898 patients.
external validation of the web-based GArFIelD-AF risk 
models in the OrbIt-AF population
The web-based GARFIELD-AF risk model was validated 
externally in an independent population from the US 
registry, ORBIT-AF (table 4). The calibration plots for 
the simplified GARFIELD-AF risk model in ORBIT-AF for 
1-year mortality, ischaemic stroke/SE and major bleed 
(in treated patients) are shown in online supplementary 
figure 1.
The predictive value of GARFIELD-AF risk models (full 
and simplified) for 1-year and 3-year all-cause mortality in 
patients enrolled in ORBIT-AF (overall and stratified with 
and without OAC treatment) is presented in table 4. The 
C-statistic for 1-year mortality was 0.75 (95% CI 0.73 to 
0.77) in the simplified risk model and 0.75 (95% CI 0.73 to 
0.77) in full risk model (table 4). For any ischaemic stroke 
or SE over 1 year, the C-statistic was 0.69 (95% CI 0.67 to 
0.71) for the GARFIELD-AF population and 0.68 (95% CI 
0.62 to 0.74) in the 9743 patients from ORBIT-AF (online 
supplementary table 4). For major bleeding over 1 year, 
this was 0.66 (95% CI 0.62 to 0.69) for the GARFIELD-AF 
population on OACs and 0.61 (95% CI 0.58 to 0.64) for 
the respective population of 7442 patients in ORBIT-AF 
(online supplementary table 5).
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Table 1 Baseline characteristics* for all patients in GARFIELD-AF and those with very low to low risk (defined by a CHA2DS2-
VASc score of 0 or 1 for men and 1 or 2 for women) compared with those with a higher risk (CHA2DS2-VASc score of ≥2 for 
men and ≥3 for women)
Very low to low risk† n=7882 Higher risk n=31 053 Overall n=38 935 P value
Age (years) 58.0 (52–63) 74.0 (67–80) 71.0 (63–78) <0.001
SBP (mm Hg) 130.0 (118–140) 134.0 (120–146) 131.0 (120–145) <0.001
DBP (mm Hg) 80.0 (70–88) 80.0 (70–88) 80.0 (70–88) 0.174
BMI (kg/m2) 27.0 (24–30) 27.0 (24–31) 27.0 (24–31) 0.023
Pulse (bpm) 83.0 (70–105) 84.0 (70–105) 84.0 (70–105) 0.326
Type of AF, n (%) <0.001
  Permanent 612 (7.8) 4326 (13.9) 4938 (12.7)
  Persistent 1188 (15.1) 4736 (15.3) 5924 (15.2)
  Paroxysmal 2686 (34.1) 8102 (26.1) 10 788 (27.7)
  Unclassified‡ 3396 (43.1) 13 889 (44.7) 17 285 (44.4)
Gender, female, n (%) 2658 (33.7) 14 649 (47.2) 17 307 (44.5) <0.001
Race, n (%) <0.001
  Caucasian 4225 (53.6) 19 932 (64.2) 24 157 (62.0)
  Hispanic-Latino 459 (5.8) 2157 (6.9) 2616 (6.7)
  Afro-Caribbean 41 (0.5) 77 (0.2) 118 (0.3)
  Asian (not Chinese) 2361 (30.0) 6183 (19.9) 8544 (21.9)
  Chinese 523 (6.6) 1543 (5.0) 2066 (5.3)
  Mixed/other 131 (1.7) 437 (1.4) 568 (1.5)
  Not declared/recorded 142 (1.8) 724 (2.3) 866 (2.2)
World region , n (%) <0.001
  Europe 3869 (49.1) 18 633 (60.0) 22 502 (57.8)
  North America 192 (2.4) 919 (3.0) 1111 (2.9)
  Latin America 606 (7.7) 2661 (8.6) 3267 (8.4)
  Asia 2982 (37.8) 7869 (25.3) 10 851 (27.9)
  Rest of world§ 233 (3.0) 971 (3.1) 1204 (3.1)
Diabetes mellitus, n (%) 220 (2.8) 8338 (26.9) 8558 (22.0) <0.001
Hypertension history, n (%) 4263 (54.1) 26 172 (84.3) 30 435 (78.2) <0.001
Heart failure, n (%) 426 (5.4) 8326 (26.8) 8752 (22.5) <0.001
Systemic embolism, n (%) 0 (0.0) 264 (0.9) 264 (0.7) <0.001
Liver disease, n (%) 47 (0.6) 160 (0.5) 207 (0.5) 0.382
History of peripheral vascular disease, n (%) 32 (0.4) 2180 (7.1) 2212 (5.7) <0.001
History of carotid artery disease, n (%) 57 (0.7) 1127 (3.7) 1184 (3.1) <0.001
History of stent use, n (%) 139 (1.8) 2425 (7.8) 2564 (6.6) <0.001
History of CABG, n (%) 33 (0.4) 1127 (3.7) 1160 (3.0) <0.001
History of stroke, n (%) 0 (0.0) 3030 (9.8) 3030 (7.8) <0.001
History of alcohol abuse, n (%) 289 (4.2) 501 (1.9) 790 (2.4) <0.001
History of bleeding, n (%) 108 (1.4) 916 (3.0) 1024 (2.6) <0.001
Kidney disease, n (%) 225 (3.3) 3813 (14.2) 4038 (12.0) <0.001
NSAID/Cox-2 inhibitor, n (%) 2052 (26.0) 9138 (29.4) 11 190 (28.7) <0.001
Antithrombotic at diagnosis of AF, n (%)
Antiplatelet 2588 (32.8) 11 496 (37.0) 14 084 (36.2) <0.001
NOAC 1631 (20.7) 7173 (23.1) 8804 (22.6) <0.001
VKA 2531 (32.1) 13 960 (45.0) 16 491 (42.4) <0.001
Note: The baseline analyses for the low-to-intermediate group provided midway results, between the very low to low risk and high risk groups, which are detailed 
in full in the appendix.
P value comparison of very low to low risk versus higher risk patients.
*Median with 25th and 75th percentiles for continuous variables, N (%) for categorical.
†Very low to low risk is defined by a CHA2DS2-VASc score of 0 or 1 for men and 1 or 2 for women.
‡The term unclassified is used when the type of AF could not be accurately determined in the short interval between diagnosis of AF and enrolment into the study.
§Rest of world: Australia, Egypt and South Africa.
AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass graft; Cox-2, cyclooxygenase-2; DBP, diastolic blood pressure; GARFIELD-AF, Global 
Anticoagulant Registry in the FIELD-Atrial Fibrillation; NSAID, non-steroidal anti-inflammatory drug; NOAC, new (or non-vitamin K) oral anticoagulant; SBP, systolic 
blood pressure; VKA, vitamin K antagonists.
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In analyses of all ORBIT-AF patients and those stratified 
with and without OAC treatment, the performance of the 
GARFIED-AF risk model was comparable with CHA2DS2-
VASc for the prediction of ischaemic stroke/SE at 1-year 
and 3-year follow-up (online supplementary table 4) and 
comparable with the ATRIA score in predicting major 
bleed in patients on OAC treatment (online supplemen-
tary table 5).
DIsCussIOn
Large-scale trials of NOACs21–28 have raised awareness of 
the potential benefits of anticoagulation for patients with 
AF and at least one risk factor for stroke/SE. Observational 
studies including GARFIELD-AF7 have demonstrated that, 
over time, patients are increasingly likely to be anticoag-
ulated (57% in 2010–2011, rising to 71% in 2014–2015 
in GARFIELD-AF among patients whom clinicians believe 
have a risk of stroke). However, despite guideline recom-
mendations,1–3 observational studies also demonstrate 
overuse of OACs in low-risk patients and underuse in 
high-risk patients in comparison with predicted use based 
on the CHA2DS2-VASc score and guideline recommenda-
tions.25–27 The GARFIELD-AF study found that patients 
with a CHA2DS2-VASc score of 0 in men, 1 in women were 
at very low risks of stroke (4 out of 1579). The implications 
are that risks may not outweigh benefits in such patients. 
It is also likely that underuse of OAC in patients with high 
risk of stroke is because of the perceived risk of bleeding. 
The findings from GARFIELD-AF indicate that factors 
beyond those included in the composite of variables for 
stroke risk scores appear to influence prescribing deci-
sions on anticoagulation. Current risk scores are complex 
(and do not reflect all risk factors, eg, renal insufficiency) 
and do not allow simultaneous prediction of ischaemic 
stroke/SE, bleeding risk and mortality.
The rationale behind this report is to provide clinicians 
with a more accurate and integrated method for strati-
fying patients according to their risks of death, stroke 
and major bleeding, and thereby facilitate decisions on 
prescribing or withholding anticoagulation and hence 
encourage greater guideline adherence.
By including all-cause mortality as a new element of the 
risk model, we hope that this will also encourage a more 
holistic approach to the management of patients with 
AF as well as aiding decisions on anticoagulation. As the 
Figure 1 One-year Kaplan-Meier event rates by CHA2DS2-VASc score for all-cause mortality, ischaemic stroke/systemic 
embolism and haemorrhagic stroke/major bleed. F, female.
Table 2 One-year Kaplan-Meier event rates in patients with 
a CHA2DS2-VASc 0–2 (men) or 1–3 (women) compared with 
remaining cohort (CHA2DS2-VASc score of ≥3 for men and 
≥4 for women)
Event
CHA2DS2-VASc 0–2 
(men) or 1–3 (women)
Remaining 
cohort
All-cause mortality, 
n (%)
341 (2.0) 1226 (5.9)
Ischaemic 
stroke/systemic 
embolism, n (%)
128 (0.8) 345 (1.7)
Haemorrhagic 
stroke/major bleed, 
n (%)
67 (0.7) 199 (1.4)
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new model is more accurate than HAS-BLED in identi-
fying those at higher bleeding risk, this affords clinicians 
with a more reliable basis for taking steps to more closely 
monitor patients and modify any potentially reversible 
bleeding risks.
Initiatives such as the GARFIELD-AF model may enable 
guideline groups in the future to recommend antico-
agulation treatment based on thresholds (according to 
predicted event rates) for stroke, major bleeding and 
all-cause mortality, rather than using conventional risk 
scores.
The GARFIELD-AF score has the potential to be incor-
porated into routine electronic record systems and to 
automatically calculate mortality, stroke and bleeding 
risks based on routinely collected data. This obviates the 
current need for separate stroke and bleeding risk calcu-
lations for each patient and allows the clinician to evaluate 
all these risks when deciding on whether to recommend 
anticoagulation. As healthcare systems increasingly adopt 
electronic health records for the management of patients, 
this will allow users to base treatment decisions on more 
precise measures of risk, including risks of mortality, 
stroke and bleeding using a single risk scoring system.
For patients with AF and clearly elevated stroke risk, 
guidelines recommend anticoagulation irrespective of a 
CHA2DS2-VASc score of 2, 3 or more (provided the risks 
of bleeding are not excessive). However, differentiation 
of those with low stroke risk is more challenging. Few 
studies include sufficiently high numbers of patients to 
accurately assess lower risk patients. The populations used 
to derive CHA2DS2-VASc, for example, contained very 
few very low risk patients (103 patients had a CHA2DS2-
VASc score of 0, and 162 patients a score of 1).4 Although 
CHA2DS2-VASc was subsequently reassessed using data 
from Danish29 and Swedish national registries,30 the value 
of CHA2DS2-VASc in defining patients with a truly low risk 
of stroke is uncertain.31
This study demonstrates that a novel computer-gener-
ated risk model, derived from GARFIELD AF, is superior to 
CHA2DS2-VASc in predicting ischaemic stroke/SE overall, 
and in very low to low risk patients with a CHA2DS2-VASc 
score of 0 or 1 (for men) or 1 or 2 (for women) who may 
not benefit from anticoagulation (as defined by the 2016 
ESC Guidelines6).
Notably, the contemporary data from GARFIELD-AF 
showed that patients with AF being considered for anti-
coagulation have lower risks of ischaemic stroke/SE than 
seen in older reports. In GARFIELD-AF, the rate of isch-
aemic stroke/SE per 100-person years (1.6%) is less than 
half the previously reported rate of 3.9% (95% CI 1.7% 
to 7.6% unadjusted for aspirin) reported by Lip et al in 
201017 for patients with a CHA2DS2-VASc score of 3.0 (ie, 
Table 3 Comparison of the performance of the new GARFIELD-AF risk model with CHA2DS2-VASc (death, stroke or systemic 
embolism) or HAS-BLED* for major bleeding in all patients overall and by treated and untreated with anticoagulation and also 
for patients with lower stroke risk.
Events
C-index
P value of test for one risk model over 
the other
GARFIELD-AF risk 
model
CHA2DS2-VASc 
(HAS-BLED for 
bleeding)*
GARFIELD-AF risk 
model
CHA2DS2-VASc 
(HAS-BLED for 
bleeding)*
All patients
All-cause mortality 0.77 (0.76–0.78) 0.66 (0.64–0.67) <0.001 0.165
Anticoagulant treated 0.75 (0.73–0.77) 0.65 (0.63–0.66) <0.001 0.186
Anticoagulant untreated 0.78 (0.77–0.80) 0.68 (0.66–0.70) <0.001 0.507
Ischaemic stroke/systemic embolism 0.69 (0.67–0.71) 0.64 (0.61–0.66) <0.001 0.006
Anticoagulant treated 0.67 (0.64–0.71) 0.64 (0.60–0.67) <0.001 0.020
Anticoagulant untreated 0.69 (0.65–0.72) 0.65 (0.61–0.68) <0.001 0.047
Major bleed (anticoagulant treated) 0.66 (0.62–0.69) 0.64 (0.61–0.68)* <0.001 0.001*
Very low to low risk patients
CHA2DS2-VASc score of 0 or 1 (men) and 1 or 2 (women); HAS-BLED 0 for bleeding
All-cause mortality 0.69 (0.64–0.75) 0.50 (0.45–0.55) <0.001 0.383
Ischaemic stroke/systemic embolism 0.65 (0.56–0.73) 0.59 (0.50–0.67) 0.004 0.108
Major bleed (anticoagulant treated) 0.60 (0.47–0.73) 0.55 (0.53–0.56)* 0.299 0.403*
Low to intermediate or higher risk patients (sensitivity analysis)
CHA2DS2-VASc score 0, 1 or 2 (men) and 1, 2 or 3 (women); HAS-BLED score 0 or 1 for bleeding
All-cause mortality 0.72 (0.70–0.75) 0.56 (0.54–0.59) <0.001 0.377
Ischaemic stroke/systemic embolism 0.67 (0.63–0.72) 0.58 (0.54–0.62) <0.001 0.087
Major bleed (anticoagulant treated) 0.64 (0.58–0.71) 0.62 (0.58–0.65)* 0.001 1.000*
GARFIELD-AF, Global Anticoagulant Registry in the FIELD-Atrial Fibrillation.
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the mean score in the GARFIELD-AF cohort). This prob-
ably reflects the impact of anticoagulation and the higher 
proportion of patients who are considered for anticoag-
ulants, compared with data from populations collected 
before 2010.
The GARFIELD-AF model performed significantly 
better than CHA2DS2-VASc for all- cause mortality. 
This is unsurprising since the GARFIELD-AF model 
assesses multiple variables at the same time, while the 
CHA2DS2-VASc score was designed only to assess isch-
aemic stroke.
As well as the full GARFIELD-AF model for all-cause 
mortality, we derived a simplified GARFIELD-AF 
risk tool for all-cause mortality (plus the original risk 
models for stroke/SE or bleeding) for easy use in 
diverse healthcare systems via the web or with a portable 
electronic device. The simplified tool performed as 
well among patients treated with OACs as among 
Figure 2 Receiver operating characteristic curves and 1 year Kaplan-Meier curves, dividing the data at median predicted risk, 
in: (A) all GARFIELD-AF patients and (B) very low to low risk patients (CHA2DS2-VASc of 0 or 1 for men and 1 or 2 for women). 
The sample sizes for the three groups in the overall population are 39 898, 39 898 and 25 677, respectively. Eighty-five per 
cent of patients were still in the cohort by the end of the 1-year period. The median 1 year risk for the three overall KM figures 
are 2.7% death, 0.95% ischaemic stroke/SE, 0.92% haemorrhagic stroke or major bleed. The median 1 year risk for the three 
lower risk KM figures are: 0.92% death, 0.43% ischaemic stroke/SE, 0.35% haemorrhagic stroke or major bleed. SE, systemic 
embolism.
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non-anticoagulated patients and was validated using 
an independent contemporary registry from the USA, 
ORBIT-AF.
A potential limitation of our analyses is that the 
GARFIELD risk tool was developed on all patients. 
Patients who are not prescribed anticoagulation treat-
ment do not have the same characteristics and base-
line features as those who are anticoagulated. For these 
reasons, the GARFIELD-AF risk tool was developed on 
all patients and included oral anticoagulants as an adjust-
ment factor to account for the change in risk after antico-
agulation is used.
Furthermore, we were not able to conduct an external 
validation of GARFIELD-AF risk tool in the low risk 
patients because ORBIT-AF did not recruit sufficient 
low-risk patients for this analysis. We anticipate that by 
making this risk score available, others will be able to test 
the performance of the GARFIELD-AF risk tool in large 
national datasets with the full spectrum of risk.
Overall, we recognise that the calibration of the new 
scores in the ORBIT population was not as good as in the 
original cohort because ORBIT-AF included patients with 
prevalent AF whereas AF-GARFIELD included new onset 
AF, and hence risk characteristics and outcomes differed.
We recognised there are other differences in the risk 
characteristics and outcomes between the GARFIELD-AF 
and ORBIT-AF populations, including the higher use of 
anticoagulation in the ORBIT-AF population from the 
USA. Although broad global representation is a strength 
of the GARFIELD-AF score, it is recognised that there 
are wide variations in outcomes and treatment practices 
across countries with different healthcare systems. Cali-
bration to the regional averages rather than overall aver-
ages provided some refinement to the estimates of risk. 
We would encourage others to test the performance of 
GARFIELD-AF score in various large national or regional 
datasets.
Despite a stringent model derivation, there were a few 
surprising findings in the factors included in the models. 
For example, ‘history of bleeding’ (which may be surro-
gate for suboptimal OAC therapy) was not independently 
predictive of future bleed but appeared to be an indepen-
dent predictor for ischaemic stroke (see online supple-
mentary table 2). Similarly, vascular disease was among 
the variables in the bleeding risk model. This may due to 
confounding with dual or triple antithrombotic therapy 
in the registry, but even with AP in the model, the term 
‘vascular disease’ remained significant (p=0.007).
Finally, the GARFIELD-AF model reflects the limita-
tions of data collected in routine practice. For example, 
it should be noted that the presence and severity of 
renal disease, as a factor in the GARFIELD-AF score, was 
determined by clinicians and the risk calculation was not 
supplemented by the collection of laboratory values for 
kidney function. Although it is recognised that additional 
variables, including certain biomarkers, may have value 
for improved prediction of the risk of outcome events,32 
these are not routinely collected in clinical practice. In 
order to validate the GARFIELD-AF risk tool in different 
geographic populations and various datasets, we would 
Figure 3 Calibration of GARFIELD-AF risk model for each end point in the GARFIELD-AF population. GARFIELD-AF, Global 
Anticoagulant Registry in the FIELD-Atrial Fibrillation; SE, systemic embolism.
Table 4 Evaluation of performance (C-statistic (95% CIs)) 
of the GARFIELD-AF risk models (full and simplified) in 
predicting all-cause mortality in patients enrolled in ORBIT-
AF (overall and stratified with and without OAC treatment)
GARFIELD-AF
Full risk model
GARFIELD-AF 
Simplified risk 
model
1-year mortality 0.75 (0.73 to 0.77) 0.75 (0.73 to 0.77)
  Anticoagulant 
treated
0.74 (0.72 to 0.77) 0.74 (0.71 to 0.76)
  Anticoagulant 
untreated
0.77 (0.73 to 0.80) 0.76 (0.72 to 0.79)
3-year mortality 0.74 (0.73 to 0.76) 0.74 (0.73 to 0.75)
  Anticoagulant 
treated
0.73 (0.72 to 0.75) 0.73 (0.71 to 0.75)
  Anticoagulant 
untreated
0.76 (0.73 to 0.78) 0.76 (0.74 to 0.78)
GARFIELD-AF, Global Anticoagulant Registry in the FIELD-Atrial 
Fibrillation; OAC, oral anticoagulant.
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encourage further evaluation of its performance in 
diverse large national datasets.
Conclusions
The GARFIELD-AF risk model predicted all-cause 
mortality, stroke/SE and major bleeding including haem-
orrhagic stroke with an accuracy that was superior to 
CHA2DS2-VASc (and also to HAS-BLED for bleeding), in 
the overall population and in patients with a lower risk 
of stroke. The simplified GARFIELD-AF risk tool, with 
potential web applications, performed as well among 
patients treated with OACs as among non-anticoagulated 
patients and was validated using an independent contem-
porary registry. Use of an integrated risk predictor, such 
as the GARFIELD-AF risk tool, has the potential to assist 
clinicians in applying evidence-based guidelines to anti-
coagulation decisions for patients with AF and possible 
stroke risk.
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